AFG
ALNY icon

Atomi Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atomi Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Sell
716
-218
-23% -$65.8K 0.01% 1183
2026
Q1 		$309K Buy
934
+27
+3% +$9.19K 0.01% 931
2025
Q4 		$361K Sell
907
-35
-4% -$15.5K 0.01% 838
2025
Q3 		$430K Buy
942
+275
+41% +$112K 0.01% 709
2025
Q2 		$218K Buy
+667
New +$185K 0.01% 1001

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atomi Financial Group's ALNY Position: Q2 2026 in Review

Atomi Financial Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2026, selling an estimated $65.8K and leaving 716 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #1183.

Atomi Financial Group first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $430K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Atomi Financial Group held 716 shares of Alnylam Pharmaceuticals worth $215K as of Q2 2026.
  • Atomi Financial Group sold 218 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $65.8K.
  • Alnylam Pharmaceuticals made up 0.01% of Atomi Financial Group's portfolio in Q2 2026, its #1183 holding.
  • Atomi Financial Group first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Atomi Financial Group's Alnylam Pharmaceuticals position peaked at $430K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Atomi Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.